Core Viewpoint - Inhibrx Biosciences, Inc. announces significant leadership changes with the departure of co-founder and Chief Scientific Officer Dr. Brendan Eckelman, who will establish a new private biotechnology company, and the appointments of Dr. Carlos Bais as CSO and David Matly as President [1][2][3][4]. Leadership Changes - Dr. Brendan Eckelman is leaving Inhibrx to become the founder and CEO of a new biotechnology company, with an exclusive license agreement in place for certain technologies previously pursued by Inhibrx [2]. - Dr. Carlos Bais, previously Executive Vice President of Translational Sciences, will take over as CSO, bringing a strong scientific background and expertise in late-stage development [5][6]. - David Matly has been promoted to President while retaining his roles as Chief Commercial and Business Development Officer, overseeing various functions including clinical development and operations [4][5]. Financial and Strategic Implications - The agreement with Dr. Eckelman’s new company includes an upfront payment upon the completion of initial funding and future development milestones, indicating potential financial implications for Inhibrx [2]. - David Matly played a key role in the asset sale of INBRX-101 to Sanofi for up to $2.2 billion in 2024, highlighting his experience in commercial strategy and business development [4]. Company Overview - Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, utilizing diverse protein engineering methods [9]. - The current clinical pipeline includes ozekibart (INBRX-109) and INBRX-106, with key data readouts expected in 2025 [9].